The effect of aging on the utilization of chemotherapy for metastatic breast cancer: A population-based study

Cancer Investigation

Volumn 15, Issue 3, 1997, Pages 199-203

  Fetting, John H ^a   Comstock, George W ^b   Eby, Sharon ^b   Huelskamp, Anne Marie ^b   Sullivan, Sue Anne ^b   Zahurak, Marianna ^b   Gerber, Jonathan ^b   Kass, Frederic H ^b   Smith, Richard ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

Age; Breast cancer; Chemotherapy; Treatment

Indexed keywords

DOXORUBICIN; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; AGING; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; DEATH CERTIFICATE; DRUG EFFECT; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0030946589     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039715     Document Type: Article

References (24)

1. Silliman RA, Guadagnoli K, Weitberg AB, et al: Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol Med Sci 44:M46-50, 1989.
2. Chu J, Dichr P, Feigl P, et al: The effect of age on the care of women with breast cancer in community hospitals. J Gerontol 42:185-190, 1987.
3. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 338:1-15 and 339:71-85,1992.
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 338:1-15 and 339:71-85,1992.
5. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994.
6. Gelman RS, Taylor SG: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer. The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413, 1984.
7. Begg CB, Elson PJ, Carbone PP: A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols. In: Cancer in the Elderly, edited by R Yancik, JW Yates, New York, Springer, 1989, pp 149-163.
8. Dresdale A, Bonow RO, Wesley R, et al: Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52:51-60, 1983.
9. Fisher B, Redmond C, Dimitrov NC, et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen receptor negative tumors. N Engl J Med 320:473-478, 1989.
10. Mansour EG, Gray R, Shatila AH, et al: Efficacy of adjuvant chemotherapy in high risk node-negative breast cancer. N Engl J Med 320:485-490, 1989.
11. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast cancer. N Engl J Med 330:1253-1259, 1994.
12. Christman K, Muss HB, Case LD, et al: Chemotherapy of metastatic breast cancer in the elderly. JAMA 268:57-62, 1992.
13. Charlson M, Szatrowski TP, Peterson J, et al: Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251, 1994.
14. Cox DR: The Analysis of Binary Data, London, Methuen, 1970.
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457-481, 1958.
16. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:170-174, 1959.
17. Cox DR: Regression models and life tables. J Roy Statist Soc 34:187-220, 1972.
18. Benner SE, Fetting JH, Brenner MH: A stopping rule for standard chemotherapy for metastatic breast cancer: lessons from a survey of Maryland medical oncologists. Cancer Invest 12:451-455,1994.
19. Newcomb PA, Carbone PP: Reports: Cancer treatment and age: Patient perspectives. J Natl Cancer Inst 85:1580-1584, 1993.
20. Garber JE, Henderson IC: The use of chemotherapy in metastatic breast cancer. Hematol/Oncol Clin North Am 3:807-821, 1989.
21. Coates A, Gebski V, Stat M, et al: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490-1495, 1987.
22. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992.
23. Wennberg J, Gittelsohn A: Small area variations in health care delivery. Science 182:1108-1112, 1973.
24. Winn RJ, Greisinger AJ, Bitsura JM, et al: Patterns of chemotherapy usage in advanced metastatic breast cancer. Proc ASCO 13:171, 1994.